{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:23:20Z","timestamp":1648740200341},"reference-count":73,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.medcli.2013.09.018","type":"journal-article","created":{"date-parts":[[2013,11,16]],"date-time":"2013-11-16T06:00:33Z","timestamp":1384581633000},"page":"73-79","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tratamiento de la poliquistosis renal autos\u00f3mica dominante"],"prefix":"10.1016","volume":"142","author":[{"given":"Roser","family":"Torra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2013.09.018_bib0005","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0272-6386(83)80044-4","article-title":"Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980","volume":"2","author":"Iglesias","year":"1983","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.medcli.2013.09.018_bib0010","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1681\/ASN.V7102142","article-title":"Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2","volume":"7","author":"Torra","year":"1996","journal-title":"J Am Soc Nephrol"},{"issue":"1 Suppl 1","key":"10.1016\/j.medcli.2013.09.018_bib0015","article-title":"US renal data system 2010 annual data report","volume":"57","author":"Collins","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.medcli.2013.09.018_bib0020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM199307293290508","article-title":"Autosomal dominant polycystic kidney disease","volume":"329","author":"Gabow","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.018_bib0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10157-012-0706-3","article-title":"Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: A single center experience","volume":"17","author":"Ozkok","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0030","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0035","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2013.09.018_bib0050","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0092-8674(94)90137-6","article-title":"The polycystic kidney disease 1 gene encodes a 14kb transcript and lies within a duplicated region on chromosome 16","volume":"77","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.medcli.2013.09.018_bib0055","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","article-title":"PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein","volume":"272","author":"Mochizuki","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.medcli.2013.09.018_bib0060","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMra1010172","article-title":"Ciliopathies","volume":"364","author":"Hildebrandt","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.018_bib0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ncpneph0070","article-title":"Mechanisms of disease: Autosomal dominant and recessive polycystic kidney diseases","volume":"2","author":"Torres","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0070","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0075","doi-asserted-by":"crossref","first-page":"C389","DOI":"10.1152\/ajpcell.1996.270.1.C389","article-title":"A role for CFTR in human autosomal dominant polycystic kidney disease","volume":"270","author":"Hanaoka","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0085","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.medcli.2013.09.018_bib0090","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.4161\/cc.5.21.3408","article-title":"Regulation of mTOR by polycystin-1: Is polycystic kidney disease a case of futile repair?","volume":"5","author":"Weimbs","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.medcli.2013.09.018_bib0095","first-page":"1","article-title":"Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families","volume":"328","author":"Dalgaard","year":"1957","journal-title":"Acta Med Scand Suppl"},{"key":"10.1016\/j.medcli.2013.09.018_bib0100","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMc061638","article-title":"Volume progression in polycystic kidney disease","volume":"355","author":"Brosnahan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.018_bib0105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2008.558","article-title":"Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months","volume":"75","author":"Kistler","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.medcli.2013.09.018_bib0115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.medcli.2013.09.018_bib0120","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrneph.2012.236","article-title":"Polycystic kidney disease: Tolvaptan in ADPKD-TEMPO 3:4 trial results","volume":"9","author":"Kelsey","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0130","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1681\/ASN.2006060603","article-title":"Water for ADPKD? Probably, yes","volume":"17","author":"Torres","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0135","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.mog.0000218958.40441.fd","article-title":"Drug-induced liver disease","volume":"22","author":"Lewis","year":"2006","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0140","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0145","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2215\/CJN.03950510","article-title":"Water prescription in autosomal dominant polycystic kidney disease: A pilot study","volume":"6","author":"Wang","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0150","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.medcli.2013.09.018_bib0155","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medcli.2013.09.018_bib0160","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2013.09.018_bib0165","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: Effects of somatostatin analogue octreotide","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","article-title":"Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial","volume":"59","author":"Chrispijn","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0175","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepato-renal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2013.09.018_bib0180","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01360210","article-title":"Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases","volume":"5","author":"Torres","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0185","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.018_bib0190","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.018_bib0195","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0200","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ndt\/gfs519","article-title":"mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): The question remains open","volume":"28","author":"Jardine","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2013.09.018_bib0205","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/ki.1992.195","article-title":"Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease","volume":"41","author":"Gabow","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.medcli.2013.09.018_bib0210","doi-asserted-by":"crossref","first-page":"F775","DOI":"10.1152\/ajprenal.00370.2003","article-title":"The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease","volume":"287","author":"Loghman-Adham","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0215","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1523-1755.2003.00776.x","article-title":"Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease","volume":"63","author":"Schrier","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.medcli.2013.09.018_bib0220","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.2215\/CJN.01460210","article-title":"Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark","volume":"5","author":"Orskov","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0225","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.ajkd.2011.01.023","article-title":"Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: A population-based study","volume":"57","author":"Patch","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.medcli.2013.09.018_bib0230","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT polycystic kidney disease trials: Design and implementation","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0235","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.09.018_bib0240","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1081\/JDI-120015682","article-title":"Does type 2 diabetes mellitus delay renal failure in autosomal dominant polycystic kidney disease?","volume":"24","author":"Backenroth","year":"2002","journal-title":"Ren Fail"},{"issue":"12 Suppl","key":"10.1016\/j.medcli.2013.09.018_bib0245","doi-asserted-by":"crossref","first-page":"44S","DOI":"10.1592\/phco.31.12.44S","article-title":"Beyond metformin: Initiating combination therapy in patients with type 2 diabetes mellitus","volume":"31","author":"Goldman-Levine","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.medcli.2013.09.018_bib0250","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/ndt\/gfr744","article-title":"The impact of type ii diabetes mellitus in patients with autosomal dominant polycystic kidney disease","volume":"27","author":"Reed","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2013.09.018_bib0255","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1681\/ASN.2007060665","article-title":"Src inhibition ameliorates polycystic kidney disease","volume":"19","author":"Sweeney","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0260","doi-asserted-by":"crossref","first-page":"C522","DOI":"10.1152\/ajpcell.00163.2010","article-title":"c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation","volume":"301","author":"Elliott","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0265","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0700499104","article-title":"Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease","volume":"104","author":"Leuenroth","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.medcli.2013.09.018_bib0270","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/ndt\/gfp777","article-title":"Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD","volume":"25","author":"Leuenroth","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2013.09.018_bib0275","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/hep.25872","article-title":"Cyclic AMP\/PKA-dependent paradoxical activation of Raf\/MEK\/ERK signaling in polycystin-2 defective mice treated with sorafenib","volume":"56","author":"Spirli","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2013.09.018_bib0280","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1093\/ndt\/gfr432","article-title":"The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis","volume":"26","author":"Buchholz","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2013.09.018_bib0285","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature05348","article-title":"Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine","volume":"444","author":"Bukanov","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.medcli.2013.09.018_bib0290","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.4161\/cc.22375","article-title":"CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD","volume":"11","author":"Bukanov","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.medcli.2013.09.018_bib0295","doi-asserted-by":"crossref","first-page":"F1176","DOI":"10.1152\/ajprenal.00130.2012","article-title":"Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth","volume":"303","author":"Li","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0300","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1681\/ASN.2007070828","article-title":"Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease","volume":"19","author":"Yang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0305","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MNH.0b013e3282b974a6","article-title":"Regulation of renal ion transport by the calcium-sensing receptor: An update","volume":"16","author":"Huang","year":"2007","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.medcli.2013.09.018_bib0310","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1681\/ASN.2008090927","article-title":"Calcimimetic inhibits late-stage cyst growth in ADPKD","volume":"20","author":"Gattone","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0315","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/ndt\/gfn527","article-title":"Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease","volume":"24","author":"Wang","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2013.09.018_bib0320","doi-asserted-by":"crossref","first-page":"F1464","DOI":"10.1152\/ajprenal.90542.2008","article-title":"Attenuated, flow-induced ATP release contributes to absence of flow-sensitive, purinergic Cai2+ signaling in human ADPKD cyst epithelial cells","volume":"296","author":"Xu","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0325","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1681\/ASN.2010070728","article-title":"Inhibition of the P2X7 receptor reduces cystogenesis in PKD","volume":"2","author":"Chang","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0330","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1093\/hmg\/ddr338","article-title":"Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways","volume":"20","author":"Takakura","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.medcli.2013.09.018_bib0335","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1073\/pnas.1103816108","article-title":"Polycystin-1 regulates STAT activity by a dual mechanism","volume":"108","author":"Talbot","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.medcli.2013.09.018_bib0340","doi-asserted-by":"crossref","first-page":"18067","DOI":"10.1073\/pnas.1111966108","article-title":"Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease","volume":"108","author":"Olsan","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.medcli.2013.09.018_bib0345","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nm.2171","article-title":"Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models","volume":"16","author":"Natoli","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.medcli.2013.09.018_bib0350","doi-asserted-by":"crossref","first-page":"F1193","DOI":"10.1152\/ajprenal.00419.2010","article-title":"Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: In vivo evidence from a Pkd1-deletion model","volume":"300","author":"Leonhard","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0355","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejphar.2010.12.008","article-title":"Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways","volume":"654","author":"Gao","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0360","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2174\/1874467211205020292","article-title":"PPAR-gamma agonists in polycystic kidney disease with frequent development of cardiovascular disorders","volume":"5","author":"Nagao","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.medcli.2013.09.018_bib0365","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/hmg\/11.15.1731","article-title":"Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant","volume":"11","author":"Muto","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.medcli.2013.09.018_bib0370","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ajpath.2011.04.036","article-title":"Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients","volume":"17","author":"Caroli","year":"2011","journal-title":"Am J Pathol"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313006568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313006568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T13:17:44Z","timestamp":1647091064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313006568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0025775313006568"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.09.018","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento de la poliquistosis renal autos\u00f3mica dominante","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2013.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}